An international consensus approach to the management of atypical hemolytic uremic syndrome in children, Pediatr Nephrol, vol.31, pp.15-39, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02149335
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults, Clin J Am Soc Nephrol, vol.8, pp.554-62, 2013. ,
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin J Am Soc Nephrol, vol.5, pp.1844-59, 2010. ,
Clinical presentation and outcome in a series of 88 patients with the cblC defect, J Inherit Metab Dis, vol.37, pp.831-871, 2014. ,
Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy, Orphanet J Rare Dis, vol.9, p.161, 2014. ,
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome, Nat Genet, vol.45, pp.531-567, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01064383
Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States, J Infect Dis, vol.192, pp.1988-95, 2005. ,
Trends in US hospital stays for Streptococcus pneumoniae-associated hemolytic uremic syndrome, Pediatr Infect Dis J, vol.32, pp.731-766, 2013. ,
Streptococcus pneumoniaeassociated hemolytic uremic syndrome among children in North America, Pediatr Infect Dis J, vol.30, pp.736-775, 2011. ,
Strategies for surveillance of pediatric hemolytic uremic syndrome: Foodborne Diseases Active Surveillance Network (FoodNet), Clin Infect Dis, vol.54, issue.5, pp.424-455, 2000. ,
Surveillance du syndrome hémolytique et urémique post-diarrhéique chez l'enfant de moins de 15 ans en France en, 2014. ,
Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network, Eur J Pediatr, vol.175, pp.465-73, 2016. ,
Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls, BMC Infect Dis, vol.14, p.320, 2014. ,
Risk factors for Shiga toxin-producing Escherichia coli-associated human diseases, Microbiol Spectr, vol.2, 2014. ,
Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany, N Engl J Med, vol.365, pp.1771-80, 2011. ,
German outbreak of Escherichia coli O104:H4 associated with sprouts, N Engl J Med, vol.365, pp.1763-70, 2011. ,
Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000-2010: epidemiologic features and comparison with E. coli O157 infections, Foodborne Pathog Dis, vol.10, pp.453-60, 2013. ,
, Annual epidemiological report 2014-food-and waterborne diseases and zoonoses. Shiga toxin/verocytotoxin-producing Escherichia coli infection, 2014.
A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience, JM, vol.109, pp.27-33, 2016. ,
An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome, Pediatr Nephrol, vol.29, pp.1967-78, 2014. ,
The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice, J Clin Invest, vol.122, pp.759-76, 2012. ,
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis, J Immunol, vol.187, pp.172-80, 2011. ,
Update on Streptococcus pneumoniae associated hemolytic uremic syndrome, Curr Opin Pediatr, vol.25, pp.203-211, 2013. ,
Management of hemolytic uremic syndrome, Presse Med, vol.41, pp.115-150, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02149335
Loss of DGK? induces endothelial cell activation and death independently of complement activation, Blood, vol.125, pp.1038-1084, 2015. ,
Cobalamin C defect: natural history, pathophysiology, and treatment, J Inherit Metab Dis, vol.34, pp.127-162, 2011. ,
Homocysteine and thrombosis: from basic science to clinical evidence, Thromb Haemost, vol.94, pp.907-922, 2005. ,
Cobalamin C defect associated with hemolytic-uremic syndrome, J Pediatr, vol.120, pp.934-971, 1992. ,
Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis, Proc Natl Acad Sci, vol.91, pp.6369-73, 1994. ,
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome, Blood, vol.112, pp.4948-52, 2008. ,
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome, Proc Natl Acad Sci, vol.104, pp.240-285, 2007. ,
Atypical hemolytic-uremic syndrome, N Engl J Med, vol.361, pp.1676-87, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01793663
Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases, Medicine, vol.91, pp.195-205, 2012. ,
Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer, J Oncol Pract, vol.12, pp.523-553, 2016. ,
Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome, Br J Haematol, vol.166, pp.802-807, 2014. ,
VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, vol.358, pp.1129-1165, 2008. ,
Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review, J Gastrointest Oncol, vol.5, pp.30-33, 2014. ,
Eculizumab and drug-induced haemolytic-uraemic syndrome, Clin Kidney J, vol.6, pp.484-85, 2013. ,
Drug-induced thrombotic microangiopathy: a systematic review of published reports, Blood, vol.125, pp.616-634, 2015. ,
Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the BloodCenter of Wisconsin, Am J Hematol, vol.90, pp.406-416, 2015. ,
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder, Bone Marrow Transplant, vol.41, pp.917-935, 2008. ,
A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury, Blood Rev, vol.29, pp.191-204, 2015. ,
Transplantation-associated thrombotic microangiopathy: twenty-two years later, Bone Marrow Transplant, vol.30, pp.709-724, 2002. ,
Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange, Bone Marrow Transplant, vol.45, pp.699-704, 2010. ,
Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy, Blood, vol.122, pp.2003-2010, 2013. ,
The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy, Blood, vol.127, pp.989-96, 2016. ,
Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, Transplantation, vol.96, pp.217-240, 2013. ,
Use of Eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC, Transplantation, vol.99, pp.1953-59, 2015. ,
Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy, Biol Blood Marrow Transplant, vol.20, pp.518-543, 2014. ,
Complement mutationassociated de novo thrombotic microangiopathy following kidney transplantation, Am J Transplant, vol.8, pp.1694-701, 2008. ,
Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report, Clin Nephrol, vol.83, pp.125-154, 2015. ,
Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation-a case report, Transplant Proc, vol.43, pp.2097-101, 2011. ,
Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab, Transplantation, vol.92, pp.42-43, 2011. ,
Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy, Clin Infect Dis, vol.35, pp.1534-1574, 2002. ,
Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer, Presse Med, vol.41, pp.177-88, 2012. ,
Thrombotic microangiopathy and hypothermia in an HIV-positive patient: importance of cytomegalovirus infection, Scand J Infect Dis, vol.36, pp.234-271, 2004. ,
Thrombotic microangiopathy (TMA) and stroke due to human herpesvirus-6 (HHV-6) reactivation in an adult receiving high-dose melphalan with autologous peripheral stem cell transplantation, Am J Hematol, vol.76, pp.156-62, 2004. ,
Complement factor C4d is a common denominator in thrombotic microangiopathy, J Am Soc Nephrol, vol.26, pp.2239-2286, 2015. ,
Renal vascular lesions in lupus nephritis, Medicine, vol.76, pp.355-68, 1997. ,
Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab, Am J Kidney Dis, vol.65, pp.127-157, 2015. ,
Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy, Pediatr Nephrol, vol.30, pp.167-72, 2015. ,
The pathogenesis of the antiphospholipid syndrome, N Engl J Med, vol.368, pp.1033-1077, 2013. ,
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome, J Clin Invest, vol.112, pp.1644-54, 2003. ,
Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury, Blood, vol.110, pp.2423-2454, 2007. ,
)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator, Blood, vol.118, issue.2, pp.2774-83, 2011. ,
Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome, J Clin Rheumatol, vol.21, pp.311-324, 2015. ,
Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report, Medicine, vol.93, p.143, 2014. ,
A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab, Transplantation, vol.98, pp.17-18, 2014. ,
The spectrum of renal involvement in patients with inflammatory myopathies, Medicine, vol.93, pp.33-41, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01859438
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney Int, vol.82, pp.454-64, 2012. ,
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis, Clin J Am Soc Nephrol, vol.10, pp.2143-51, 2015. ,
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations, J Am Soc Nephrol, vol.21, pp.859-67, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00512540
Eculizumab for atypical hemolytic uremic syndrome in pregnancy, Obstet Gynecol, vol.122, pp.487-89, 2013. ,
Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management, J Nephrol, vol.28, pp.641-686, 2015. ,
Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia, N Engl J Med, vol.374, pp.13-22, 2016. ,
The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome, J Matern Fetal Neonatal Med, vol.25, pp.2322-2347, 2012. ,
Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort, PLoS Med, vol.8, p.1001013, 2011. ,
Renal cortical necrosis in postpartum hemorrhage: a case series, Am J Kidney Dis, vol.68, pp.50-57, 2016. ,
Loss of diacylglycerol kinase epsilon in mice causes endothelial distress and impairs glomerular Cox-2 and PGE2 production, Am J Physiol Renal Physiol, vol.310, pp.895-908, 2016. ,
DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN, J Am Soc Nephrol, vol.24, pp.377-84, 2013. ,
Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement, J Am Soc Nephrol, vol.25, pp.1786-98, 2014. ,
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype, J Am Soc Nephrol, vol.24, pp.475-86, 2013. ,
New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3, Biosci Rep, vol.34, p.146, 2014. ,
Analysis of protein-coding genetic variation in 60,706 humans, Nature, vol.536, pp.285-91, 2016. ,
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med, vol.17, pp.405-429, 2015. ,
Thrombomodulin mutations in atypical hemolytic-uremic syndrome, N Engl J Med, vol.361, pp.345-57, 2009. ,
Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome, J Am Soc Nephrol, vol.25, pp.55-64, 2014. ,
Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae, Clin Infect Dis, vol.54, pp.1413-1434, 2012. ,
Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death, J Pediatr, vol.166, pp.1022-1051, 2015. ,
Long-term outcomes of Shiga toxin hemolytic uremic syndrome, Pediatr Nephrol, vol.28, pp.2097-105, 2013. ,
Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection, Am J Kidney Dis, vol.41, p.4, 2003. ,
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience, PLoS One, vol.5, p.10208, 2010. ,
Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases, Am J Kidney Dis, vol.63, pp.40-48, 2014. ,
The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy, J Am Soc Hypertens, vol.10, pp.352-59, 2015. ,
Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome, Clin J Am Soc Nephrol, vol.5, pp.1218-1246, 2010. ,
The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak, Brain, vol.135, pp.1850-59, 2012. ,
The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study, Arch Dis Child, vol.101, pp.387-91, 2016. ,
Peripheral gangrene in children with atypical hemolytic uremic syndrome, Pediatrics, vol.131, pp.331-366, 2013. ,
Distal angiopathy and atypical hemolytic uremic syndrome: clinical and functional properties of an anti-factor H IgA? antibody, Am J Kidney Dis, vol.66, pp.331-367, 2015. ,
Skin involvement in atypical hemolytic uremic syndrome, Am J Kidney Dis, vol.63, pp.652-55, 2014. ,
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome, J Am Soc Nephrol, vol.21, pp.2180-87, 2010. ,
Cardiovascular complications in atypical haemolytic uraemic syndrome, Nat Rev Nephrol, vol.10, pp.174-80, 2014. ,
Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement, Pediatr Nephrol, vol.29, pp.1103-1109, 2014. ,
Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab, BMJ Case Rep, 2016. ,
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay, Br J Haematol, vol.129, pp.93-100, 2005. ,
Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli, Arch Pediatr Adolesc Med, vol.166, pp.902-911, 2012. ,
The utility and public health implications of PCR and whole genome sequencing for the detection and investigation of an outbreak of Shiga toxin-producing Escherichia coli serogroup O26:H11, Epidemiol Infect, vol.143, pp.1672-80, 2015. ,
How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome ,
, Br J Haematol, vol.164, pp.759-66, 2014.
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nat Rev Nephrol, vol.8, pp.643-57, 2012. ,
Nephrotic syndrome and thrombotic microangiopathy caused by cobalamin C deficiency, Pediatr Nephrol, vol.30, pp.1203-1209, 2015. ,
Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency, Am J Kidney Dis, vol.63, pp.119-142, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01011789
Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency, Lancet, vol.386, pp.1011-1023, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01850500
Cobalamin C deficiency-associated thrombotic microangiopathy: uncommon or unrecognised?, Lancet, vol.386, p.1012, 2015. ,
Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP, Blood, vol.123, pp.3733-3771, 2014. ,
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy, Blood, vol.124, pp.1715-1741, 2014. ,
Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome, Am J Kidney Dis, vol.65, pp.968-69, 2015. ,
Modified Ham test for atypical hemolytic uremic syndrome, Blood, vol.125, pp.3637-3683, 2015. ,
Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, Clin Infect Dis, vol.49, pp.1480-85, 2000. ,
Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome, Pediatr Nephrol, vol.30, pp.345-52, 2015. ,
Early volume expansion and outcomes of hemolytic uremic syndrome, Pediatrics, vol.137, pp.1-9, 2016. ,
Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis, JAMA, vol.288, pp.996-1001, 2002. ,
Shiga toxin-producing Escherichia coli infection, antibiotics, and risk of developing hemolytic uremic syndrome: a meta-analysis, Clin Infect Dis, vol.62, pp.1251-58, 2016. ,
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study, BMJ, vol.345, p.4565, 2012. ,
Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis, Clin Infect Dis, vol.55, pp.33-41, 2012. ,
Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Pediatr Infect Dis J, vol.31, pp.37-41, 2012. ,
Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4, JAMA, vol.307, pp.1046-52, 2012. ,
Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study, Clin Infect Dis, vol.56, pp.1132-1172, 2013. ,
Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal, J Antimicrob Chemother, vol.70, pp.2440-2486, 2015. ,
An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children, Clin Infect Dis, vol.55, pp.753-59, 2012. ,
Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry, Nephrol Dial Transplant, vol.27, pp.3807-3822, 2012. ,
Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial, Lancet, vol.378, pp.1166-73, 2011. ,
Immunoadsorption in patients with haemolytic uraemic syndrome, Lancet, vol.379, pp.517-535, 2012. ,
, Immunoadsorption in patients with haemolytic uraemic syndrome-Authors' reply, Lancet, vol.379, pp.518-537, 2012.
New therapeutic developments against Shiga toxin-producing Escherichia coli, Microbiol Spectr, vol.2, 2014. ,
Eculizumab in severe Shiga-toxin-associated HUS, N Engl J Med, vol.364, pp.2561-63, 2011. ,
Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab, Nephrol Dial Transplant, vol.29, pp.565-72, 2014. ,
Response to eculizumab in Escherichia coli O157: H7-induced hemolytic uremic syndrome with severe neurological manifestations, Clin Pediatr, vol.54, pp.387-89, 2015. ,
Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement, Medicine, vol.94, p.1000, 2015. ,
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome, Kidney Int, vol.89, pp.701-712, 2016. ,
A prospective study of paediatric patients with atypical hemolytic uremic syndrome treated with eculizumab: 1-year update (abstract), Pediatr Nephrol, vol.30, p.1564, 2015. ,
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, N Engl J Med, vol.368, pp.2169-81, 2013. ,
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies, Kidney Int, vol.87, pp.1061-73, 2015. ,
Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial, Am J Kidney Dis, vol.68, pp.84-93, 2016. ,
Eculizumab inhibits thrombotic microangiopathy, and improves renal function in adult atypical hemolytic uremic syndrome patients: 1-year update, J Am Soc Nephrol, vol.25, p.751, 2014. ,
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS, Blood, vol.125, pp.3253-62, 2015. ,
Eculizumab-related progressive multifocal leukoencephalopathy, Neurology, vol.86, pp.399-400, 2016. ,
Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment, J Nephrol, 2016. ,
Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan, Clin Exp Nephrol, vol.20, pp.265-72, 2015. ,
Remission of aHUS neurological damage with eculizumab, Clin Kidney J, vol.8, pp.232-268, 2015. ,
Success of eculizumab in the treatment of atypical hemolytic uremic syndrome, Pediatr Nephrol, vol.30, pp.783-89, 2015. ,
Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab, Int Med Case Rep J, vol.8, pp.235-274, 2015. ,
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome, J Thromb Haemost, vol.12, pp.1440-1448, 2014. ,
Complement. First of two parts, N Engl J Med, vol.344, pp.1058-66, 2001. ,
Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy, Pediatr Int, vol.57, pp.313-330, 2015. ,
Successful treatment of DEAP-HUS with eculizumab, Pediatr Nephrol, vol.29, pp.841-51, 2014. ,
Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab, Ren Fail, vol.36, pp.1119-1140, 2014. ,
Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome, Pediatrics, vol.133, pp.1764-68, 2014. ,
Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab, Ann Intern Med, vol.159, p.76, 2013. ,
Eculizumab for atypical hemolytic uremic syndrome in pregnancy, Obstet Gynecol, vol.122, pp.487-89, 2012. ,
Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria, N Engl J Med, vol.373, pp.1032-1071, 2015. ,
Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome, Am J Transplant, vol.13, pp.663-75, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00945715